EUCTR2008-000885-21-NL进行中(未招募)不适用
The effect of betahistine 48 mg three times daily on motion sickness - betahistine
TNO0 个研究点目标入组 0 人开始时间: 2008年2月29日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中(未招募)
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Age 18-30 years at Day 01 of the study
- •Female volunteers should take oral contraceptives (combined or progestogen only). This is to attenuate hormonal influences on the susceptibility to motion sickness. The menstrual cycle has been shown to influence motion sickness susceptibility (Golding et al. 2004).
- •Body Mass Index (BMI) 18-28 kg/m2
- •Healthy as assessed by health questionnaire (Pbetahistine F02; in Dutch) and a physical examination limited to auscultation of heart and lung, blood pressure and heart rate
- •Susceptibility to motion sickness is more than 35 on Golding’s MSSQ scale.
- •Participation on a voluntary basis
- •Having given their written informed consent
- •Willing to comply with the study procedures (e.g. the possible provocation of motion sickness)
- •Willing to accept use of all anonymous data, including publication, and the confidential use and storage of all data
- •Willing to accept the disclosure of the financial benefit of participation in the study to the authorities concerned
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Participation in any clinical trial including blood sampling and/or administration of substances up to 30 days before Day 01 of this study
- •Having a history of medical or surgical events that may significantly affect the study outcome as vestibular, cardiovascular, pulmonary, gastrointestinal, neurological, psychiatric, hepatic, renal, hematological or other organic abnormality or pathology, including: asthma, ulcus pepticum urticaria, or allergic complaints as a rash or allergic rhinitis).
- •Prescribed medication that may interfere with the study outcome
- •Inclination to hyperventilation (Nijmegen questionnaire score > 23)
- •Not able to undergo the familiarization tests inside the moving base-simulator Desdemona (see below)
- •Alcohol consumption females > 21 or units/week; males >28 units/week
- •Pregnancy or breastfeeding
- •TNO personnel and their close relatives
- •Not having a general practitioner
- •Not willing to accept information-transfer concerning participation in the study, or information regarding his/her health, findings at anamnesis or physical examination and eventual adverse events to and from his general practitioner
研究者
相似试验
尚未招募
2 期
The effect of betahistine 48 mg three times daily on motion sicknessbewegingsziektemotion disturbance10027667motion sicknessNL-OMON32365TNO26
已完成
不适用
Efficacy of high dosage of betahistine in patients with unilateral peripheral vestibulopathyunilateral peripheral vestibulopathyJPRN-UMIN000017711niversity of Tokushima225
招募中
不适用
Effect of betahistine in treating in patients with peripheral vestibular diseaseperipheral vestibular diseaseJPRN-UMIN000032573niversity of Toyama15
已完成
3 期
Aripiprazle in ADHD and ODDAttention deficit/hyperactivity disorder.Attention deficit/hyperactivity disorderIRCT20160530028182N6Sanandaj University of Medical Sciences76
已完成
1 期
Pharmacokinetic profile of betahistine blood concentration with and without selegiline in healthy volunteers - a mono-center, open-labeled phase I trialhealthy volunteersDRKS00023352MU Klinikum Neurologische Klinik und Poliklinik15
